Dermatology-ophthalmology collaborations are needed in dupilumab-associated ocular events
- PMID: 33476727
- DOI: 10.1016/j.jaad.2021.01.043
Dermatology-ophthalmology collaborations are needed in dupilumab-associated ocular events
Conflict of interest statement
Conflicts of interest Dr Shi is a stock shareholder of Learn Health and has served as an advisor, investigator, and/or speaker for Sanofi Genzyme, Regeneron, AbbVie, Burt's Bees, Dermira, Eli Lilly, Novartis, Pfizer, Galderma, LEO Pharma, Sun Pharma, Menlo Therapeutics, GpSkin, and Skin Actives Scientific. Dr Hsiao has served as an advisor for Novartis. Authors Thompson and Yu have no conflicts of interest to declare.
Comment on
-
Dupilumab shows long-term effectiveness in a large cohort of treatment-refractory atopic dermatitis patients in daily practice: 52-Week results from the Dutch BioDay registry.J Am Acad Dermatol. 2021 Apr;84(4):1000-1009. doi: 10.1016/j.jaad.2020.08.127. Epub 2020 Sep 16. J Am Acad Dermatol. 2021. PMID: 32946967
Publication types
MeSH terms
Substances
LinkOut - more resources
Other Literature Sources